Jean-Pierre M. Ayoub

939 total citations
22 papers, 266 citations indexed

About

Jean-Pierre M. Ayoub is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean-Pierre M. Ayoub has authored 22 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Jean-Pierre M. Ayoub's work include Cancer Treatment and Pharmacology (10 papers), Advanced Breast Cancer Therapies (6 papers) and PARP inhibition in cancer therapy (5 papers). Jean-Pierre M. Ayoub is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Advanced Breast Cancer Therapies (6 papers) and PARP inhibition in cancer therapy (5 papers). Jean-Pierre M. Ayoub collaborates with scholars based in Canada, United States and Australia. Jean-Pierre M. Ayoub's co-authors include Laura Pearce, Eric Winquist, Nancy Wainman, Jennifer J. Knox, Ajit Shah, Elizabeth A. Eisenhauer, Gregory K. Reid, Josep Tabernero, Timothy R. Asmis and Fernando Rivera and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Oncologist.

In The Last Decade

Jean-Pierre M. Ayoub

20 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean-Pierre M. Ayoub Canada	8	160	139	63	34	31	22	266
Scott A. Lawrence United States	4	155 1.0×	132 0.9×	67 1.1×	23 0.7×	39 1.3×	4	263
Jianjun Xiao China	9	89 0.6×	115 0.8×	72 1.1×	24 0.7×	75 2.4×	16	222
Amanda J. Loch Canada	4	135 0.8×	89 0.6×	63 1.0×	16 0.5×	44 1.4×	5	210
Sook Kyung South Korea	8	105 0.7×	104 0.7×	65 1.0×	9 0.3×	50 1.6×	29	229
S.M. Jamshedur Rahman United States	3	197 1.2×	170 1.2×	84 1.3×	25 0.7×	56 1.8×	4	299
Tonći Šuštić Netherlands	7	192 1.2×	72 0.5×	54 0.9×	19 0.6×	53 1.7×	9	255
Nicolas Dorvault France	7	161 1.0×	119 0.9×	46 0.7×	13 0.4×	66 2.1×	12	237
Louis Masclef Canada	5	138 0.9×	50 0.4×	37 0.6×	14 0.4×	33 1.1×	9	194
Elisa Minenza Italy	9	59 0.4×	182 1.3×	117 1.9×	23 0.7×	31 1.0×	12	245
Simona Frezzini Italy	6	113 0.7×	93 0.7×	42 0.7×	11 0.3×	89 2.9×	8	231

Countries citing papers authored by Jean-Pierre M. Ayoub

Since Specialization

Citations

This map shows the geographic impact of Jean-Pierre M. Ayoub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Pierre M. Ayoub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Pierre M. Ayoub more than expected).

Fields of papers citing papers by Jean-Pierre M. Ayoub

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Pierre M. Ayoub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Pierre M. Ayoub. The network helps show where Jean-Pierre M. Ayoub may publish in the future.

Co-authorship network of co-authors of Jean-Pierre M. Ayoub

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Pierre M. Ayoub. A scholar is included among the top collaborators of Jean-Pierre M. Ayoub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Pierre M. Ayoub. Jean-Pierre M. Ayoub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chia, Stephen, Andrew Redfern, Jean-Pierre M. Ayoub, et al.. (2025). A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).. Journal of Clinical Oncology. 43(17_suppl). 2 indexed citations

Ayoub, Jean-Pierre M., Mustapha Tehfé, Marie Florescu, et al.. (2023). Reflex testing for RAS and BRAF mutations in metastatic colorectal cancer: A single Canadian academic oncology center experience.. Journal of Clinical Oncology. 41(4_suppl). 86–86. 1 indexed citations

Han, Hyo S., Banu Arun, Bella Kaufman, et al.. (2020). Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.. Journal of Clinical Oncology. 38(15_suppl). 1091–1091. 1 indexed citations

Arun, Banu, Hyo S. Han, Bella Kaufman, et al.. (2020). Abstract PD4-01: First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial. Cancer Research. 80(4_Supplement). PD4–1. 6 indexed citations

Puhalla, Shannon L., Véronique Dièras, Banu Arun, et al.. (2020). Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.. Journal of Clinical Oncology. 38(15_suppl). 1097–1097. 2 indexed citations

Ayoub, Jean-Pierre M., Normand Blais, Alexandra Desnoyers, et al.. (2019). Implementing DPYD*2A genotyping in clinical practice, the Quebec experience.. Journal of Clinical Oncology. 37(4_suppl). 650–650. 2 indexed citations

Miller, Wilson H., Rahima Jamal, Eftihia Cocolakis, et al.. (2018). Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).. Journal of Clinical Oncology. 36(5_suppl). 185–185. 1 indexed citations

Ayoub, Jean-Pierre M., et al.. (2018). Prognosis in young women under 40 with brain metastasis from breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1091–1091. 1 indexed citations

Jamal, Rahima, Réjean Lapointe, Eftihia Cocolakis, et al.. (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for ImmunoTherapy of Cancer. 5(1). 83–83. 38 indexed citations

10.

Tehfé, Mustapha, Marie Florescu, Denis Soulières, et al.. (2015). Phase I and II studies of the decitabine–genistein drug combination in advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). e13556–e13556. 7 indexed citations

11.

Han, Hyo S., Véronique Dièras, Michael Friedländer, et al.. (2015). Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology. 33(28_suppl). 155–155. 9 indexed citations

12.

Aubin, F., et al.. (2015). Streptozocin-based treatment in advanced neuroendocrine tumors (NETs): A single institution experience.. Journal of Clinical Oncology. 33(15_suppl). e15179–e15179.

13.

Puhalla, Shannon, Hyo S. Han, Véronique Dièras, et al.. (2015). Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology. 33(15_suppl). TPS1102–TPS1102. 2 indexed citations

14.

García‐Carbonero, Rocio, Fernando Rivera, Joan Maurel, et al.. (2014). An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer. The Oncologist. 19(4). 350–351. 51 indexed citations

15.

Raymond, Nicolas, Jean-Pierre M. Ayoub, Richard Létourneau, et al.. (2014). FOLFIRINOX in the real-world setting: The multicentric experience of six Canadian institutions.. Journal of Clinical Oncology. 32(3_suppl). 367–367. 8 indexed citations

16.

Jamal, Rahima, Karl Bélanger, Jennifer Friedmann, et al.. (2014). A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. Journal of Clinical Oncology. 32(15_suppl). 9066–9066. 7 indexed citations

17.

Ayoub, Jean-Pierre M., Richard Létourneau, Rasmy Loungnarath, et al.. (2014). FOLFIRINOX in the real world setting: The multicentric experience of six Canadian institutions.. Journal of Clinical Oncology. 32(15_suppl). e15232–e15232. 4 indexed citations

18.

García‐Carbonero, Rocio, Fernando Rivera, Joan Maurel, et al.. (2012). A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.. Journal of Clinical Oncology. 30(4_suppl). 533–533. 17 indexed citations

19.

Winquist, Eric, Jennifer J. Knox, Jean-Pierre M. Ayoub, et al.. (2006). Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Investigational New Drugs. 24(2). 159–167. 105 indexed citations

20.

Ayoub, Jean-Pierre M., et al.. (2005). Unknown Primary Carcinomas: Diagnosis and Management. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact